Filtered By:
Specialty: Cardiology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 800 results found since Jan 2013.
Linc00657 promoted pyroptosis in THP-1-derived macrophages and exacerbated atherosclerosis via the miR-106b-5p/TXNIP/NLRP3 axis
This study was designed to investigate the effects and underlying mechanisms of linc00657 in atherogenesis. The results showed that ox-LDL treatment significantly induced pyroptosis in human THP-1-derived macrophages. The secretion levels of LDH and pro-inflammatory factors were markedly enhanced, and the integrity of plasma membranes was disrupted in ox-LDL-treated THP-1-derived macrophages. These effects were significantly compensated after transfection with linc00657 siRNA and became more evident by linc00657 overexpression. Moreover, the effects of linc00657 overexpression on pyroptosis of THP-1-derived macrophages can...
Source: Atherosclerosis - September 21, 2023 Category: Cardiology Authors: Yin Liang Xiao-Dan Xu Xi Xu Yang-Bo Cai Zi-Xian Zhu Lin Zhu Kun Ren Source Type: research
FUS regulates the alternative splicing of cell proliferation genes related to atherosclerosis
Exp Biol Med (Maywood). 2023 Sep 9:15353702231187642. doi: 10.1177/15353702231187642. Online ahead of print.ABSTRACTFUS plays a significant role as an RNA-binding protein in several cellular processes, including RNA splicing, DNA repair, and transcriptional regulation. However, the RNA-binding capacity of FUS in atherosclerosis is unclear. We aimed to study the functions of FUS in inflammatory regulation through the role of the splicing factor. We knocked down FUS with siRNA to further study the overall transcriptional level and select alternative splicing (AS) of FUS regulation in human umbilical vein endothelial cells (H...
Source: Atherosclerosis - September 9, 2023 Category: Cardiology Authors: Jianjun Hou Shaobing Yang Ying Guo Ning Yan Shaobin Jia Source Type: research
Positive Topline Results for Antihypertensive Zilebesiran Positive Topline Results for Antihypertensive Zilebesiran
The investigational siRNA therapeutic showed consistent and sustained reductions in systolic blood pressure in a phase 2 study of adults with hypertension.Medscape Medical News
Source: Medscape Cardiology Headlines - September 8, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Effect of GRK4 on renal gastrin receptor regulation in hypertension
CONCLUSION: GRK4 participates in the development of hypertension by regulating the phosphorylation of renal CCKBR leading to impaired CCKBR function and water and sodium retention. Knockdown of GRK4 restored the function of CCKBR. The enhanced co-connection between GRK4 and CCKBR may be an important reason for the hyperphosphorylation of GRK4 and CCKBR involved in the pathogenesis of hypertension.PMID:37641972 | DOI:10.1080/10641963.2023.2245580
Source: Clinical and Experimental Hypertension - August 29, 2023 Category: Cardiology Authors: Xuewei Xia Yongchun Zeng Zhuxin Li Hao Luo Wei Wang Yanji He Bingjun Lu Jingwen Guo Ken Chen Xiang Xu Source Type: research
Updates in Drug Treatment of Severe Hypertriglyceridemia
AbstractPurpose of ReviewTo provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG).Recent FindingssHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication of sHTG. Therapeutic options with novel mechanisms of action have been developed, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targetingAPOC3 andANGPTL3. The review discusses also 2 abandoned d...
Source: Current Atherosclerosis Reports - August 29, 2023 Category: Cardiology Source Type: research
Musashi-2 binds with Fbxo6 to induce Rnaset2 ubiquitination and chemokine signaling pathway during vascular smooth muscle cell phenotypic switch in atherosclerosis
CONCLUSION: Our findings demonstrated that MSI2 could bind with Fbxo6 to induce Rnaset2 ubiquitination and the activation of chemokine signaling pathway during VSMC phenotypic switch in AS.PMID:37633478 | DOI:10.1016/j.cellsig.2023.110869
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Tao Zhang Shusheng Wu Rongwei Xu Shuguang Zhang Minghai Wang Jie Li Source Type: research
TRIM65 Suppresses oxLDL-induced Endothelial Inflammation by Interaction with VCAM-1 in Atherogenesis
CONCLUSION: Our studies indicate that TRIM65 attenuates the endothelial inflammatory response by targeting VCAM-1 for ubiquitination and provides a potential therapeutic target for the inhibition of endothelial inflammation in AS.PMID:37608612 | DOI:10.2174/0929867331666230822152350
Source: Atherosclerosis - August 23, 2023 Category: Cardiology Authors: Xiao-Feng Ma Yi-Ren Zhou Zhi-Xiang Zhou Hui-Ting Liu Bo-Bin Zhoua Nian-Hua Deng Kun Zhou Zhen Tian Ze-Fan Wu Xi-Yan Liu Ming-Gui Fu Zhi-Sheng Jiang Source Type: research
Ferrostatin-1 Blunts Right Ventricular Hypertrophy and Dysfunction in Pulmonary Arterial Hypertension by Suppressing the HMOX1/GSH Signaling
AbstractFerroptosis plays a critical role in pulmonary arterial hypertension (PAH)-induced right ventricular (RV) dysfunction, but key genes remain largely unclear. We here identified HMOX1 as an essential ferroptosis-related differentially expressed gene in PAH by bioinformatic analysis using FerrDb, GSE119754, and GSE3675 datasets, respectively. Notably, there were marked increases in HMOX1 and iron levels in RV of monocrotaline-induced PAH rats with reduced TAPSE levels. More importantly, treatment with ferrostatin-1 effectively attenuated RV hypertrophy, remodeling, myocardial fibrosis, and dysfunction in PAH rats. In ...
Source: Journal of Cardiovascular Translational Research - August 21, 2023 Category: Cardiology Source Type: research
Reduction in LDL-C following treatment with inclisiran at 2 months in a single centre lipid clinic cohort
Background and Aims: Inclisiran is a new first in class small interfering RNA (siRNA) lipid lowering drug that has been shown to be effective in reducing low-density lipoprotein cholesterol (LDL-c) in randomised controlled trials. However, real-world data of its use is currently lacking. We aimed to analyse the early effects of this drug in a tertiary centre lipid clinic.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: P. Padam, L. Barton, S. Wilson, A. David, S. Walji, F. De Lorenzo, K. Ray, B. Jones, J. Cegla Source Type: research
PCSK9 inhibitors preferences and shared decision making
Background and Aims: High risk patients who do not reach LDL-C target currently have three options: 1) addition of PCSK9 monoclonal antibody (mAb), 2) addition of a PCSK9 siRNA, or 3) no additional medication. Shared decision making is considered important in contemporary patient care. The first step is to gain insight in the preferences of patients and healthcare providers, which is the aim of our study.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: J. Mulder, K. Redekop, A. Galema-Boers, L. Kranenburg, J. Roeters Van Lennep Source Type: research
Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research
